Dr. Sheetal Ajmani joins BioTalk to discuss a topic rarely addressed in the life sciences startup world. The personal and leadership toll that accompanies building and scaling a company. A physician turned executive coach and founder of Radiant Living Institute, Dr. Ajmani works closely with founders and senior leaders navigating intense professional pressure while trying to maintain clarity in decision making.
In this conversation, she explains how exhaustion and sustained stress can quietly affect leadership judgment during critical moments such as fundraising, board interactions, regulatory setbacks, and periods of rapid growth. The discussion explores the signals that investors and advisors may overlook when a founder is struggling behind the scenes, and how the culture of “pushing through” can begin to create risk not only for individuals but for the companies they lead. Dr. Ajmani also shares practical ways founders can stabilize their leadership presence and maintain momentum while protecting their own well-being.
Listen now on your favorite platform:
Apple: https://apple.co/4swmqJR
Spotify: https://bit.ly/47vWndC
YouTube Podcasts (audio): https://bit.ly/46OmeNO
Amazon Music Podcasts: https://amzn.to/4cwQbFN
iHeartRadio Podcasts: https://ihr.fm/3PqJfAg
TuneIn: https://bit.ly/4lioh2r
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Dr. Sheetal Ajmani is a physician, keynote speaker, and executive coach who helps leaders and founders reclaim their well-being and lead with authenticity. After nearly two decades in clinical medicine, she founded Radiant Living Institute, where she integrates science, psychology, and the mind-body connection to help individuals make meaningful and sustainable changes in their lives and leadership. Dr. Ajmani is also the host of the Essential Self-Care podcast and co-author of the Amazon bestselling book Doctoring, Better. For more information, visit https://www.radiantlivinginstitute.com/.
BioHealth Innovation, Inc. (BHI) is pleased to announce the appointment of Dr. Nilay Shah to its Board of Directors. A physician–executive with more than 20 years of experience in global clinical development and commercial strategy, Dr. Shah brings deep expertise in advancing innovative therapies from early development through regulatory approval and market entry.
Dr. Shah currently serves as Senior Vice President and Global Head of Ophthalmology at Emmes, where he leads the company’s fastest-growing therapeutic division and serves on the Executive Management Committee. Over the course of his tenure, he has helped scale the organization into a global CRO serving biotech innovators across North America, Europe, Latin America, and Asia. His experience spans Phase I through Phase III trials, FDA and EMA engagement, pharmacovigilance, and strategic alliances with emerging and growth-stage life sciences companies.
Throughout his career, Dr. Shah has served as a Medical Monitor for various studies and also has directed complex, multi-national clinical programs, including global trials supporting market authorization of novel biologics and the first autonomous AI-based diagnostic system approved by the FDA for the detection of diabetic retinopathy. He has also built and led high-performing cross-functional teams, strengthened commercial strategy, and partnered closely with venture-backed companies navigating regulatory and operational milestones.
Beyond his executive leadership, Dr. Shah has played an active role in Maryland’s innovation ecosystem. He serves as an advisor and reviewer for multiple TEDCO venture programs and is a Board Member of the Baltimore Innovation Initiative, where he supports early-stage founders in clinical strategy, regulatory planning, and commercialization.
“Nilay brings a rare combination of physician insight, global clinical operations leadership, and commercial acumen,” said BHI President and CEO, Rich Bendis. “He understands what it takes to move a therapy from concept to approval, and he has done it at scale. As we continue to support entrepreneurs and growing companies across the BioHealth Capital Region and beyond, his experience will strengthen our ability to guide companies through critical development and regulatory inflection points.”
“I am honored to join the Board of BioHealth Innovation at a pivotal time for the BioHealth Capital Region,” said Nilay C. Shah, MBBS (MD), Senior Vice President and Global Head of Ophthalmology at Emmes. “We are witnessing a powerful convergence of breakthrough science, artificial intelligence, and precision medicine, but innovation only matters if it translates into approved and accessible therapies. Throughout my career in global clinical development, I have seen how early strategic guidance and disciplined execution accelerate that journey. BioHealth Innovation uniquely bridges scientific innovation and commercialization, and I look forward to supporting entrepreneurs as they navigate critical regulatory and development milestones to bring transformative therapies to patients faster.”
Dr. Shah’s appointment reflects BHI’s continued focus on assembling a board with hands-on experience in therapeutic development, regulatory strategy, venture engagement, and global operations. His perspective will support the organization’s mission to accelerate commercialization, mentor emerging companies, and expand the region’s leadership in biohealth innovation.
The BioHealth Capital Region continues to grow as one of the nation’s leading biohealth clusters, driven by research excellence, capital access, federal partnerships, and a deep bench of experienced operators. Each year, BioHealth Capital Region Week brings that momentum together under one roof.
The 12th Annual BioHealth Capital Region Week will take place September 15th through 17th, 2026, once again hosted at the US Pharmacopeia in Rockville, Maryland. Over three days, leaders from industry, government, academia, and the investment community will convene to address the opportunities and challenges shaping the future of biohealth.
The BioHealth Capital Region Forum will anchor the first two days, September 15th and 16th, featuring national and regional voices addressing policy, capital markets, innovation strategy, workforce, and the technologies shaping the next phase of growth. The Forum remains the central gathering point for strategic discussion across the ecosystem.
Planning Committees are coming together to develop a forward-looking program of keynotes and panels that reflect where the market is headed. From capital strategy and commercialization pathways to emerging technologies and public-private collaboration, the 2026 agenda will focus on practical insight and real connections that move companies forward.
The Crab Trap Competition will return on September 16th, spotlighting emerging companies across therapeutics, diagnostics, medical devices, and digital health. Applications will open this spring, and qualifying companies will have the opportunity to present live before investors and industry leaders. Additional applicants may also be invited to participate in quick-pitch sessions during the week.
The Investment Conference will close out the week on September 17th, bringing together active investors and growth-stage companies seeking capital. The conference is designed to foster direct engagement between founders and funding sources, with curated company presentations, investor panels, and structured networking. It remains one of the most targeted opportunities in the region for companies to connect with venture capital, strategic investors, and other capital partners focused on life sciences.
BioHealth Capital Region Week is designed for entrepreneurs, investors, executives, policymakers, economic development leaders, and service providers who are actively engaged in advancing life sciences companies. Whether you are raising capital, scaling operations, building partnerships, or evaluating new technologies, this week is built to deliver meaningful engagement.
We are grateful to the sponsors who have already committed to supporting 2026, including George Mason University, the Maryland Department of Commerce, Montgomery County Economic Development Corporation, NIHFCU, the NIH Office of Technology Transfer, and others who continue to invest in the region’s continued growth.
Organizations interested in sponsorship opportunities or deeper engagement are encouraged to reach out:
Rich Bendis – rbendis@biohealthinnovation.org
Andy Eckert – aeckert@biohealthinnovation.org
Please save the dates of September 15th through 17th, 2026, and plan to join us in Rockville as we continue to strengthen the BioHealth Capital Region’s position among the nation’s top biohealth hubs.
by Jonathan Kay, MPP, Managing Partner, Health Market Experts & BioHealth Innovation, Inc. Entrepreneur-in-Residence
As we conclude our Optimizing Launch Messaging series, we’ve explored how to create clear, targeted, and evidence-based messages. For our final insight, we’re focusing on a tool that’s rapidly changing the communication landscape: artificial intelligence. We’ll focus on generative AI here, and similar lessons can apply to agentic AI down the road.
Insight 7: Engage the power of AI in message optimization
When preparing for launch (or really any high-stakes communication) the strongest messages come from a partnership between humans and AI. Here’s the workflow we recommend:
A. Workshop the message development 🧠
Bring your teams together early to outline goals, target audiences, and the strategic backbone of your message.
B. Invite AI to that workshop 🤖
Use AI to generate message concepts, explore angles you may have neglected, and broaden strategic and creative possibilities. Three years ago, I wrote an article about inviting AI to the clinical care team. That’s happening more and more. Similarly, we should invite AI to our consulting workflows.
C. Refine the messages with humans 👥
Review AI-generated ideas with expert oversight to ensure accuracy, nuance, and alignment with your strategic intent.
D. Test the messages with real stakeholders 🔍
Interview stakeholders to find out how the test messages land. Focus on audiences that will make or break your launch. That could be physicians, payer decision makers, patients and their advocates, hospital executives and more.
E. Refine again before deployment 🎯
Integrate testing feedback to sharpen language, strengthen relevance, and remove confusing or misaligned elements.
F. Build in a post-launch feedback loop 🔁
See our earlier post Tactic #5 about defining and measuring success to evaluate the impact of your message, and inform your future communications.
Recently, Health Market Experts, LLC teamed up with Oakton Communications Partners and Sequencr AI for a series of webinars showcasing our point of view on the power of human + AI collaboration in message optimization for issues and crisis management. Our methods for GTM message optimization were applicable in the context of issues and crisis management, too.
Have you used AI in your messaging work? 💬 What worked well for you?
DM me if you’re interested in learning more about our point of view or engaging in one of our workshops.
If your organization is preparing to launch a new business or brand, connect with us (message me on LinkedIn) or visit https://www.healthmarketexperts.com/ to learn more about how we can help you with messaging and commercial strategy to set your business and brand on a path of success.
Written by a human. This post expands on content I previously wrote as a blog at Catalant and delivered in guest lectures at Rutgers Business School.
Visit https://www.linkedin.com/in/jonathan-kay-healthcare/ to connect with Jon on LinkedIn.
Dr. Frank Peacock and Dr. Damon R. Kuehl join BioTalk for a focused discussion on one of emergency medicine’s most persistent challenges: accurately diagnosing and predicting outcomes in mild traumatic brain injury. As Scientific Advisory Board members for BrainBox Solutions, Inc., they walk through what happens when a patient presents to the emergency department after a fall or sports injury and why current tools, including CT scans, often leave clinicians without clear answers. The conversation explores the gap between a “normal” scan and ongoing symptoms, and what missed or uncertain diagnoses can mean for patients weeks later.
Dr. Peacock outlines the HeadSMART II study and explains why combining blood biomarkers with neurocognitive testing provides a more complete assessment than biology alone. Dr. Kuehl discusses how multi-modal data, integrated through artificial intelligence, can generate an objective score to support real-time clinical decision-making and help identify patients at risk for persistent symptoms. The episode also highlights BrainBox’s leadership, including CEO Donna Edmonds, a member of the BioHealth Innovation Board of Directors, and the company’s role in advancing objective mTBI testing.
Listen now via your favorite podcast platform:
Apple: https://apple.co/4aiigz6
Spotify: https://bit.ly/4rZQWf7
iHeart: https://ihr.fm/3ZAGiPL
Amazon Podcasts: https://amzn.to/4bY0Fha
YouTube Music: https://bit.ly/4aF6SMB
TuneIn: https://bit.ly/4rXcx7V
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Dr. W. Frank Peacock IV is Professor of Emergency Medicine at Baylor College of Medicine. Chief Medical Officer at AseptiScope, and the founder of both a contract research organization called Comprehensive Research Associates, LLC and a medical education company named Emergencies in Medicine, LLC. Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital. He has >900 peer reviewed publications and is also the co-editor of multiple medical textbooks on heart failure, acute coronary syndromes, and traumatic brain injury.
Dr. Damon R. Kuehl is the Vice Chair of Research and Academic Affairs and Professor in the Department of Emergency Medicine at Virginia Tech, School of Medicine. He completed Medical School at University of Minnesota Medical School and his Emergency Medicine Residency at Stanford University. He has also completed residencies in Preventive Medicine and a Research Fellowship in the Center for Policy and Research in Emergency Medicine, at Oregon Health and Science University. Dr. Kuehl’s research primarily focuses on diagnostic and prognostic uncertainty in brain injury. He is a lead investigator for HeadSMART II and for HeadSMART Geriatrics, a NINDS funded 3 year study to develop a diagnostic tool for head trauma in older adults. He is the founder of the Carilion Brain Injury Center and also an investigator with the Virginia Tech Center for Biomechanics studying the boundary conditions associated with injuries in older adult falls.